The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MD, ACAD, RMTI and ABBV
NEW YORK, Sept. 02, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
MEDNAX, Inc. (NYSE: MD) Class Period: February 4, 2016 to July 27, 2017 Lead Plaintiff Deadline: September 10, 2018
The lawsuit alleges MEDNAX, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) the Company’s business model was not sustainable; and (2) Mednax’s growth was in fact based upon suppressing physician compensation and enforcing non-compete agreements to deter physician defections. On April 20, 2017, Mednax announced negative financial results for the first quarter of 2017. Then on July 28, 2017, during an earnings call, Mednax announced that the Company failed to complete any acquisitions of anesthesiologist practices during the second quarter and disclosed that any future acquisitions were unlikely. Following this news, shares of Mednax fell from a close of $56.49 on July 27, 2017, to a close of $47.73 per share the following day.
Get additional information about the MD lawsuit: http://www.kleinstocklaw.com/pslra-c/mednax-inc?wire=3
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Class Period: April 29, 2016 to July 9, 2018 Lead Plaintiff Deadline: September 17, 2018
Throughout the class period, ACADIA Pharmaceuticals Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) adverse events and safety concerns related to NUPLAZID threatened the drug’s initial and continuing FDA approval; (2) ACADIA engaged in business practices likely to attract regulatory scrutiny; and (3) as a result, defendants’ statements about ACADIA’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
Get additional information about the ACAD lawsuit: http://www.kleinstocklaw.com/pslra-c/acadia-pharmaceuticals-inc?wire=3
Rockwell Medical, Inc. (NASDAQ: RMTI) Class Period: March 16, 2018 to June 26, 2018 Lead Plaintiff Deadline: September 25, 2018
The complaint alleges that during the class period Rockwell Medical, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Rockwell was aware that The Centers for Medicare and Medicaid Services will not pursue Rockwell’s proposal for separate reimbursement for the drug Triferic; (2) the estimated reserves in the first quarter 2018 10-Q are misstated; (3) there was a material weakness in Rockwell’s internal controls over financial reporting; (4) consequently, Rockwell’s internal controls over financial reporting were ineffective during the Class Period; (5) Defendant Chioini withheld material information regarding Triferic from Rockwell’s auditor, corporate counsel and five independent directors of the Board; and (6) as a result, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked reasonable bases at all relevant times.
Get additional information about the RMTI lawsuit: http://www.kleinstocklaw.com/pslra-c/rockwell-medical-inc?wire=3
AbbVie Inc. (NYSE: ABBV) Class Period: May 30, 2018 Lead Plaintiff Deadline: September 24, 2018
The complaint alleges that AbbVie issued false and misleading statements, in both press releases and filings with the U.S. Securities and Exchange Commission, regarding the results of the Company’s $7.5 billion modified Dutch auction tender offer that expired on May 29, 2018 (the “Tender Offer”). Specifically, the complaint alleges that before the opening of trading on May 30, 2018, the Company announced that it expected to acquire 71.4 million of its shares tendered at or below $105 per share. As a result of this news, the price of AbbVie securities significantly increased. However, after the close of trading on May 30, 2018, the Company released materially different results for the Tender Offer due to certain omissions, announcing that the Company expected to acquire only those shares tendered at or below $103 per share. Upon this news, AbbVie shares fell from a close of $103.01 per share on May 30, 2018, to a close of $98.94 on May 31, 2018.
Get additional information about the ABBV lawsuit: http://www.kleinstocklaw.com/pslra-c/abbvie-inc?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.